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Pleiotropy refers to the phenomenon in which a genetic locus (a gene or a single variant within a gene) affects more than 1 trait or disease (1) . At the molecular level, various mechanisms underlie pleiotropy (2) (3) (4) (5) (6) . These include a single gene with multiple physiological functions (3, 5, 6) , 2 domains of a single gene product with different functions and affecting multiple phenotypes (2-6), or a gene product with a single function that affects multiple phenotypes by acting in multiple tissues (3) (4) (5) (6) . At the statistical level, a locus displaying cross-phenotype associations (association with multiple phenotypes) is often considered pleiotropic. However, cross-phenotype associations may arise due to biological pleiotropy (independent associations between a locus and multiple phenotypes (3, 6) ); mediated pleiotropy (association between a genetic locus and an intermediate phenotype that causes a second phenotype (3, 6) ); or spurious pleiotropy (artifactual associations with multiple phenotypes due to issues related to study design, confounder bias, or associations with genetic markers in strong linkage disequilibrium with multiple causal variants in different genes (6) ).
The study of pleiotropy has tremendous implications for public health. First, pleiotropy-informed analyses provide an opportunity to address the "missing heritability" problem for complex diseases (7) . A prevailing view is that large fractions of the heritable components of complex diseases are unaccounted for due to variants whose effects are too small to achieve significance in genome-wide association studies (GWAS) (8) , and one way to overcome this issue of statistical power is to conduct pleiotropy-informed analyses (9, 10) . Second, pleiotropic loci provide insights into the mechanistic underpinnings of disease comorbidity and have the potential to serve as targets for interventions that simultaneously prevent or treat multiple diseases. To realize the potential of pleiotropic loci, genetic epidemiologic studies must generate robust statistical evidence of pleiotropy.
This review provides epidemiologists with an overview of statistical tools used to detect pleiotropy. We have emphasized methods that facilitate the study of phenotypes hypothesized to share a portion of their genetic backgrounds (e.g., based on coheritability estimates from family-or population-based studies (11) (12) (13) and/or epidemiologic or clinical observations of phenotypic correlation). First, we have described univariate and multivariate methods for discovery of cross-phenotype associations. Second, we have described how mediation analysis can be used to dissect cross-phenotype associations due to biological, mediated, or spurious pleiotropy.
DISCOVERING CROSS-PHENOTYPE ASSOCIATIONS
Various methods can be used to discover cross-phenotype associations. Selecting a method involves practical and scientific considerations, including the types of data available (subject-level data vs. summary statistics) and the distributions of the phenotypes of interest (Web Figure 1 , available at https:// academic.oup.com/aje). We have described univariate and multivariate analytical options below, noting the specific hypotheses tested by each method (Table 1) as well as their relative advantages and disadvantages.
Univariate methods
A potential challenge faced when using secondary data to study pleiotropy is the unavailability of subject-level data with all phenotypes measured on the same subjects. In that case, each phenotype may be analyzed separately in different study populations, and the resulting summary statistics can be used to identify cross-phenotype associations via univariate methods.
Standard univariate approaches. A standard approach is to examine single-trait summary statistics and informally compare evidence of association at a particular locus across phenotypes (as exemplified by Willer et al. (14) ). Cross-phenotype associations are then declared for loci satisfying the significance threshold for each trait (6) . A second approach is to test loci known to be associated with a given phenotype for association with another phenotype (as exemplified by Delahanty et al. (15) ). In this case, cross-phenotype associations are declared for loci meeting the significance threshold for the second phenotype (6) . A third approach-perhaps most relevant to the study of disease phenotypes-is to identify genes involved in pathways common to all phenotypes (candidate genes) and test variants in these genes against each phenotype (as exemplified by Szczepankiewicz et al. (16) ).
While straightforward, these approaches have important limitations. The first and second tend to overlook loci with weak to moderate associations when used in a GWAS setting (6) due to stringent multiple-testing corrections (17, 18 ) that limit detection power (8) . The third approach is less affected by the multipletesting burden; however, its power may be restricted by gaps in our current understanding of mechanistic overlaps between disease phenotypes.
Meta-analyses of univariate results. Meta-analytical approaches compute a single summary statistic across study populations (i.e., across phenotypes). Methods based solely on P values (e.g., Fisher's method (19) ) ignore allelic effect direction and thus can detect associations regardless of cross-phenotype differences in magnitude and direction of the genetic effects. Conversely, methods that consider effect sizes (20, 21 ) are sensitive to crossphenotype effect heterogeneity. To accommodate moderate effect heterogeneity, random-effects models can be used (instead of fixed-effects models) (22, 23) ; nevertheless, detection power decreases in the presence of negative genetic correlations between traits (24) . Consequently, these methods tend to overlook variants with opposite directions of effect on the phenotypes.
Traditional meta-analytical approaches are easily implemented and yield powerful statistical tests when there are positive genetic correlations between traits (24). However, they do not test for cross-phenotype associations explicitly; they test the significance of the summary statistic, and the association signal may be driven by a single phenotype. To circumvent this issue, the cross-phenotype meta-analysis statistic may be used (25) . This statistic tests whether the observed trait-specific P values deviate from the null hypothesis of no additional associations beyond those already known, which is rejected if a marker is associated with at least 2, although not necessarily all, phenotypes. A limitation is that, when more than 2 phenotypes are tested, the cross-phenotype meta-analysis statistic does not alone indicate which phenotypes are associated with a given marker; post hoc analyses (e.g., the clustering analysis performed in Cotsapas et al. (25) ) are needed to resolve the set of associated phenotypes. One approach that does identify the associated traits is the subset-based meta-analysis (26) , which generalizes standard fixed-effects meta-analyses by allowing some subset of traits to have no effect. It explores all possible combinations of "non-null" models to identify the strongest association signal and evaluates its significance while accounting for the number of tests required by the subset search. Therefore, if many phenotypes are analyzed, the approach becomes computationally intensive and the multiple-testing burden decreases detection power (26) .
Traditional meta-analytical approaches require that there be no overlap in the study subjects included in the phenotypespecific univariate analyses (i.e., that the same subjects do not appear in multiple studies). Failure to account for such overlap drastically reduces statistical power (27) . One solution is to split overlapping subjects across phenotype-specific studies such that each subject contributes only 1 record to the meta-analysis. However, this strategy can also limit study power and is viable only when working with subject-level data. Alternatively, one can adjust for the correlated observations of overlapping subjects using the method shown in Lin and Sullivan (27) . Such an adjustment has been adopted to accommodate the use of shared control subjects in the subset-based meta-analysis (26) .
Pleiotropy-informed univariate approaches. Phenotypes controlled by pleiotropic loci occur together and appear to be statistically correlated. Univariate approaches that consider cross-phenotype correlations when combining trait-specific results into a single statistic are "pleiotropy-informed." One strategy is a Bayesian false-discovery rate (FDR)-based approach (9) . It uses P values from 2 single-trait GWAS to calculate a conditional FDR for each phenotype (the probability that a single nucleotide polymorphism (SNP) is not associated with the first phenotype, given that its P values for both phenotypes are below specified thresholds). To identify cross-phenotype associations, a conjunction FDR (the maximal conditional FDR in both directions) is then calculated. This minimizes the likelihood that a single phenotype drives the common association signal (9) . This method requires that the 2 GWAS be independent-or that, when analyzing 2 disease phenotypes, the 2 control groups be independent-to guarantee that observed trait-specific effect sizes are uncorrelated at null SNPs. To accommodate shared controls, conditional FDR values can be adjusted as described in Liley and Wallace (28) .
Another strategy is the trait-based association test that uses extended Simes procedure (29) . This approach combines P values from single-trait analyses conducted across overlapping subjects to arrive at a global P value, while correcting for the observed cross-phenotype correlation. Like other methods based on P values, it is robust to the direction of genetic correlation between phenotypes (24, 29) . However, it tends to be most powerful when cross-phenotype correlations are small and a locus affects only some phenotypes (30) .
To summarize, univariate methods exploit single-trait summary statistics to study cross-phenotype associations. The use of summary statistics confers flexibility to analyze phenotypes of various distributions. Moreover, because most require data from nonoverlapping populations, results will not show correlations due to phenotypic correlations and/or the linkage disequilibrium structure of the human genome (31) . A limitation is that the study populations may differ with respect to size, recruitment strategies, and quality control and inclusion criteria (31) . In addition, use of summary statistics across distinct study populations prohibits the thorough follow-up analyses needed to distinguish between cross-phenotype associations due to biological, mediated, or spurious pleiotropy.
Multivariate methods
When subject-level data are available in which all phenotypes have been measured on the same subjects, multivariate methods can be employed. Multivariate methods analyze the phenotypes jointly either directly or indirectly. All are pleiotropyinformed, using the information provided by the cross-phenotype correlation. Indirect methods. Indirect methods combine phenotypes into a single composite score (24) . A commonly used method is principal components analysis (32) . Typically, the first principal component score-which explains the largest proportion of the phenotypic variance-is used in place of the original phenotypes. A limitation of principal components analysis is that it has no genetic basis; that is, principal component scores may have low heritability. To bypass this issue, the principal component of heritability association test (PCHAT) (33) may be used. PCHAT extracts the principal components of heritability, the linear combinations of the phenotypes that optimize the variance explained by a genetic variant. In a genome-wide setting, a different principal component of heritability is calculated for each variant. As a result, PCHAT tends to be more powerful than traditional principal components analysis. Still, PCHAT power is limited by the use of cross-validation (the test statistic is calculated repeatedly using random splits of the data, and the overall statistic is derived from an integration of the individual test statistics), which reduces the effective sample size. Moreover, like principal components analysis, PCHAT is best suited for analysis of continuous, normally distributed phenotypes that jointly follow a multivariate normal distribution (34) . When analyzing dichotomous traits (e.g., 2 disease phenotypes), multinomial logistic regression can be used to model the traits jointly as a single multinomial response variable with 4 distinct categorical values denoting subjects affected by both diseases, one or the other, or neither (35) .
Direct methods. Direct methods model genetic effects directly on the traits, without changing the general format of the trait data (36) . As in traditional epidemiologic analyses, the choice of method typically depends on the phenotype distributions. If all phenotypes are normally distributed (or jointly follow a multivariate normal distribution), linear mixed-effects models (37) can be used. Linear mixed-effects models model genetic variants as fixed effects and cross-phenotype correlations as random effects (38) . If all phenotypes are dichotomous or categorical, generalized linear mixed-effects models (39) can be used. If all phenotypes are correlated survival times, Gaussian frailty models can be used (38) . Frailty models, unlike linear mixed-effects models and generalized linear mixed-effects models, require that the cross-phenotype correlation structure be prespecified. Misspecification of the correlation matrix may result in biased estimates of fixed effects. However, this bias appears to be negligible in genetic association studies (38, 40) .
If phenotypes are non-normal or a mixture of continuous and dichotomous traits, modified extended generalized estimating equations (EGEEs) (41) , canonical correlation analysis (CCA) (42), or ordinal logistic regression in MultiPhen (43) can be used. The modified EGEE approach (41) is an extension to the original EGEE framework (44) that uses a seemingly unrelated regression (45) procedure to combine generalized linear models with different link functions into a unified equation system. Modified EGEEs can also handle phenotypes with more complex distributions, and, like original EGEEs, they are robust to misspecification of the cross-phenotype correlation structure (41, 44) . CCA extends the Pearson product-moment correlation to scenarios with multiple independent and dependent variables (46) . A CCA-based approach (42) can be implemented within the PLINK software package (47) for analysis of a single SNP and multiple phenotypes. In that scenario, CCA is equivalent to a multivariate analysis of variance (48) and to a reversed ordinary least squares regression that treats the SNP as a single continuous, normally distributed dependent variable and the phenotypes as predictor variables (43) . The CCA assumption of normality of genotype distributions has been shown to increase the type 1 error rate when testing case-control or non-normal continuous phenotypes (48) . MultiPhen (43) addresses this limitation by modeling genotypes as ordinal outcomes in a reversed proportional odds logistic regression, where the phenotypes are the predictors. Thus, MultiPhen makes no assumptions regarding the phenotype distributions and can analyze categorical and non-normal continuous traits without compromising the type 1 error (43) . Still, we note that the type 1 error rate for MultiPhen is inflated when the number of phenotypes is large or, specifically, when the ratio of the number of phenotypes to the number of subjects analyzed is greater than 1:10 (30). Moreover, MultiPhen is most powerful when the genetic effects are not in the same direction as the cross-phenotype correlation (i.e., when a variant affects negatively correlated phenotypes in the same direction or positively correlated phenotypes in opposite directions) (43) .
The multivariate methods discussed thus far do not test for cross-phenotype associations explicitly; they test a global null hypothesis of no association with any phenotype, which is rejected if a locus is associated with at least 1, but not necessarily all, phenotypes. Moreover, they do not indicate which traits are associated with a genetic marker. While some methods yield information useful for resolving the association signals (e.g., CCA produces phenotype-specific weights to indicate the phenotypes' respective contributions to the association result (24, 42) , and MultiPhen produces phenotype-specific effect sizes and P values, based on the joint model including all phenotypes (24, 43)), post hoc analyses are usually necessary to interpret multivariate findings.
To bypass these issues, pleiotropy estimation and testing (49), the Lutz method (50), or a sequential likelihood-ratio test (51) may be used. Pleiotropy estimation and testing (49) explicitly tests for cross-phenotype association with 2 normally distributed phenotypes by estimating a pleiotropy correlation coefficient (the proportion of the standardized cross-trait covariance explained by genetic effects) via regression or bootstrapping approaches. The Lutz method (50)-which permutes the phenotypes and compares the observed and permuted single-trait association P values using a Hausdorff metric or a cutoffbased approach-is more general, accommodating a greater number of phenotypes and a mixture of continuous and categorical traits. However, its statistical power decreases as the number of phenotypes analyzed increases. In addition, the method fails to detect cross-phenotype associations if only a subset of traits is associated with a given locus. In contrast, the sequential likelihood-ratio test (51) systematically assesses the number of traits associated with a genetic variant as follows: First, the global null hypothesis of no association with any trait is tested, and, if rejected, a test of whether only 1 trait is associated is conducted; if the latter is significant, then the null of "k" associated traits is sequentially tested until the null hypothesis fails to be rejected. This method is reserved for analysis of continuous phenotypes and is most powerful when more than 2 traits are associated with a given locus.
Another alternative is the Bayesian unified network for conducting multivariate analysis available through the BIMBAM software (52) . Multivariate-BIMBAM is a model selection procedure that conducts exhaustive searches for subsets of variables that are highly associated with a SNP, after controlling for other relevant variables. BIMBAM discerns between phenotypes that are directly affected, indirectly affected (through other measured variables), or completely unaffected by a genetic variant, but its use is reserved for analysis of continuous, normally distributed phenotypes.
To summarize, multivariate methods model phenotypes jointly. Only some multivariate approaches provide explicit tests for cross-phenotype associations; the majority test a global null hypothesis that detects association with at least 1, but not necessarily all phenotypes. In fact, almost every method reviewed herein tests this global null hypothesis (Table 1) . What distinguishes multivariate approaches, then, is that they leverage the information provided by the cross-phenotype correlation, which is ignored when the phenotypes are modeled separately (53) . Consequently, multivariate analyses often achieve greater statistical power than standard univariate analyses even in the absence of pleiotropy (53) . This provides a considerable advantage in a GWAS setting (where power to detect associations of moderate to small effect sizes is limited by the multiple-testing burden), making multivariate analyses a powerful screening tool for cross-phenotype associations. However, given the noted constraints of the global null hypothesis, loci with significant multivariate association signals must be evaluated further (e.g., through post hoc standard univariate regression) to confirm the presence of cross-phenotype associations.
DISSECTING CROSS-PHENOTYPE ASSOCIATIONS
Genetic loci that display strong evidence of cross-phenotype associations must be evaluated further to be classified as examples of biological, mediated, or spurious pleiotropy (Figure 1) . Distinguishing between these scenarios is necessary to explain how the loci affect the phenotypes under analysis. To thoroughly dissect cross-phenotype associations, mediation analysis can be performed on these candidate pleiotropic loci.
Mediation analysis decomposes the total effect of the genetic exposure (e.g., SNP) on a phenotypic outcome into direct effects (the effect of a SNP on a phenotypic outcome that occurs independently of an intermediate variable, or mediator) and indirect effects (the effect of a SNP on the phenotypic outcome that occurs through a mediator) (54) . To perform mediation analysis, certain assumptions must be met, and we refer the reader to VanderWeele and Vansteelandt (55) for details. Briefly, mediation analysis requires that there be no unmeasured confounders of the total effect, no unmeasured confounders of the exposuremediator relationship, and no unmeasured confounders of the mediator-outcome relationship. The first and second assumptions are typically met in genetic epidemiologic studies because genetic exposures are randomized-random segregation and assortment of alleles from parent to offspring during gamete formation ensures that associations between genetic variants and phenotypic outcomes are usually not susceptible to confounding (56, 57) . The third assumption requires careful measurement and modeling of potential confounders to prevent bias (58) , restricting the use of mediation analyses to data sets in which data on such variables have been collected. Mediation analysis requires that all phenotypes be measured on the same subjects. Moreover, the data should allow the temporal sequence of the phenotypes to be teased apart, because the mediator should precede the phenotypic outcome. For phenotypes for which causal relationships are well-established (e.g., smoking and chronic obstructive pulmonary disease (COPD) (59)), designating a given phenotype as a mediator is relatively straightforward. However, this is not the case for phenotypes for which there is no prior evidence of causal relationships or for comorbid conditions exhibiting bidirectional causal relationships (e.g., obesity and asthma (60-62)), because both phenotypes would have the potential to act as mediators and/or outcome variables. Establishing temporality in these scenarios would be imperative. Moreover, to perform mediation analysis on such phenotypes, the data should come from cross-sectional or cohort designs where subjects have not been recruited on the basis of their disease status. While direct and indirect SNP effects can be estimated in case-control designs (see VanderWeele and Vansteelandt (63) for details), data from a case-control study of asthma, for example, where people with asthma are oversampled, would preclude an analysis of asthma as a mediator of the SNP-obesity association.
There are 2 general approaches to mediation analysis: the classical (Baron and Kenny (64)) approach and the causal inference approach based on counterfactual outcomes (65, 66) (Figure 2 ). The classical approach estimates direct and indirect effects by fitting 2 regression models: one for the mediator (M) and another for the phenotypic outcome (Y). The model for Y assumes that the exposure (A; in our example, the SNP) does not interact with M in its effect on Y; and, in the absence of such exposure-mediator interactions, the direct effect of A on Y is assumed to be similar at every value of M and can be effectively averaged to yield a controlled direct effect. Generally, in the presence of nonlinearity (e.g., when working on an odds ratio scale and/or in the presence of the aforementioned exposure-mediator interactions), the classical approach can yield biased estimates of the direct and indirect effects (54, 58, (65) (66) (67) . The causal inference approach overcomes this limitation, providing a more general strategy for decomposing the total effect of the SNP, irrespective of the statistical model and possible interactions (55, 63, 68) . We note that the causal inference approach uses counterfactualbased definitions of the direct and indirect effects, and we refer the reader to VanderWeele and Vansteelandt (55) and Pearl (66) for details. It is also worth noting that the 2 regression-based approaches coincide under the following scenarios (68): 1) for linear and log-linear models: in the absence of exposure-mediator interaction, and 2) for logistic models: in the absence of exposure-mediator interaction and if the outcome is rare.
It follows that an important first step when choosing a mediation approach is to test for presence of exposure-mediator interactions. This must be done separately for each candidate pleiotropic SNP by adding the appropriate cross-product terms to the regression models for Y, as shown in Figure 2 .
Mediation analysis can be implemented using macros in SAS (SAS Institute, Inc., Cary, North Carolina), SPSS (SPSS Inc., Chicago, Illinois), R (R Foundation for Statistical Computing, Vienna, Austria), or MPlus (68). These programs vary in their capacity to use data from various study designs, estimate different types of causal effects, and accommodate exposure-mediator interactions and various types of variables and/or covariates. We refer the reader to Valeri and VanderWeele (68) for a summary of available macros.
Once the direct and indirect SNP effects are quantified, cross-phenotype associations can be classified as follows:
• Biological pleiotropy: SNP A is associated with mediator M, and the total effect of SNP A on phenotypic outcome Y is equal to its direct effect (i.e., the indirect effect is equal to 0). • Mediated pleiotropy:
• Complete mediation: SNP A is associated with mediator M, and the total effect of SNP A on phenotypic Figure 2 . Regression-based approaches to mediation analysis. Mediation analysis decomposes the total effect of the genetic exposure (A; e.g., a SNP) on a phenotypic outcome (Y) into direct effects (i.e., effects occurring independently of an intermediate variable or mediator (M)) and indirect effects (i.e., effects occurring through M).
One of 2 regression-based approaches is generally used to conduct mediation analysis: the classical (Baron and Kenny (64)) approach or a causal inference approach based on counterfactual outcomes. Both require fitting regression models for M (to assess the effect of A on M, while controlling for measured confounders (C)) and for Y (to assess the effect of A on Y, while controlling for both M and C). The Baron and Kenny approach requires estimation of the following regression models:
The direct effect is given by θ 1 and the indirect effect is given by θ 2 β 1. This approach assumes that the direct effect does not depend on the value of M (i.e., that there is no exposuremediator interaction). Therefore, the direct effect is averaged across the values of M and can be interpreted as a controlled direct effect. The causal inference approach extends the classical framework to scenarios with exposure-mediator interactions by adding an appropriate cross-product term to the regression equation for Y as follows:
In this scenario, a direct effect can be calculated for each value of M (termed natural direct effects), and a controlled direct effect may also be calculated. The natural direct effect (for a change in the genetic exposure from level a* to level a) is given by (a − a*)[θ 1 + θ 3 (β 0 + β 1 a* + β′ 2 C)]; the controlled direct effect is given by (a − a*)(θ 1 + θ 3 M); and the natural indirect effect is given by (a − a*)(θ 2 β 1 + θ 3 β 1 a). For simplicity, the notation employed applies to scenarios where both M and Y are modeled via ordinary least squares regression (as presented in the literature for the classical mediation approach). However, the regression equations can be rewritten for scenarios in which M and Y are dichotomous and modeled with the appropriate link functions.
outcome Y is equal to its indirect effect (i.e., the direct effect is equal to 0). • Incomplete mediation: SNP A is associated with mediator M, and SNP A has both direct and indirect effects on phenotypic outcome Y (i.e., the total effect is equal to the sum of the direct and indirect effects). • Spurious pleiotropy: SNP A is not associated with mediator M after controlling for measured confounders.
The distinction between biological and mediated pleiotropy carries important public health implications. To illustrate these, we turn to an example from the COPD literature. Variants rs1051730 and rs803419, located in the aminoglycoside phosphotransferase domain containing 1 (AGPHD1)/cholinergic receptor nicotinic alpha 3 (CHRNA3) cluster on chromosome 15q25, display cross-phenotype associations with COPD (69) and smoking intensity (70) (71) (72) (73) . Because smoking intensity is a major environmental risk factor for COPD (59) , it was necessary to explore whether the variants were directly associated with COPD or whether the associations were partially or completely mediated by smoking. Siedlinski et al. (74) used mediation analysis to dissect the effects of these variants and found evidence of incomplete mediation-the variants had both direct and indirect effects on COPD. This suggests that intervening at the genetic level would be optimal to overcome the risk of COPD attributable to these variants, because that would target both the smoking-related and nonsmoking-related pathways resulting in COPD. While intervening to reduce smoking behavior is always beneficial, doing so would be suboptimal in this specific scenario, because there would be residual risk of COPD due to these variants.
CONCLUDING REMARKS
In this review, we described methods that can be used to generate robust statistical evidence of pleiotropy in genetic epidemiologic studies. We provided researchers with guidance for planning and interpreting the results of studies of pleiotropy and highlighted the importance of using mediation analysis to dissect cross-phenotype associations and classify them as examples of biological, mediated, or spurious pleiotropy. In particular, we illustrated that distinguishing between biological and mediated pleiotropy has the potential to inform the design of public health interventions.
